EP1833511A4 - Methode de traitement du cancer du cerveau - Google Patents

Methode de traitement du cancer du cerveau

Info

Publication number
EP1833511A4
EP1833511A4 EP06717342A EP06717342A EP1833511A4 EP 1833511 A4 EP1833511 A4 EP 1833511A4 EP 06717342 A EP06717342 A EP 06717342A EP 06717342 A EP06717342 A EP 06717342A EP 1833511 A4 EP1833511 A4 EP 1833511A4
Authority
EP
European Patent Office
Prior art keywords
brain cancer
treating brain
treating
cancer
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06717342A
Other languages
German (de)
English (en)
Other versions
EP1833511A2 (fr
Inventor
Sui Xiong Cai
Mark B Anderson
Adam Willardsen
Nilantha Sudath Sirisoma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Cytovia Therapeutics LLC
Original Assignee
Myriad Genetics Inc
Cytovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc, Cytovia Inc filed Critical Myriad Genetics Inc
Publication of EP1833511A2 publication Critical patent/EP1833511A2/fr
Publication of EP1833511A4 publication Critical patent/EP1833511A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP06717342A 2005-01-03 2006-01-03 Methode de traitement du cancer du cerveau Withdrawn EP1833511A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64126305P 2005-01-03 2005-01-03
PCT/US2006/000122 WO2006074187A2 (fr) 2005-01-03 2006-01-03 Methode de traitement du cancer du cerveau

Publications (2)

Publication Number Publication Date
EP1833511A2 EP1833511A2 (fr) 2007-09-19
EP1833511A4 true EP1833511A4 (fr) 2011-01-19

Family

ID=36648123

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06717342A Withdrawn EP1833511A4 (fr) 2005-01-03 2006-01-03 Methode de traitement du cancer du cerveau

Country Status (7)

Country Link
EP (1) EP1833511A4 (fr)
JP (1) JP2008526776A (fr)
KR (1) KR20070117547A (fr)
CN (1) CN101287369A (fr)
AU (1) AU2006204052A1 (fr)
CA (1) CA2592971A1 (fr)
WO (1) WO2006074187A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050267182A1 (en) 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
KR20100016385A (ko) * 2007-04-10 2010-02-12 미리어드 파마슈티칼스, 인코포레이티드 뇌종양 치료방법
FR2932180B1 (fr) * 2008-06-04 2012-08-10 Centre Nat Rech Scient Dihydro iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de la polymerisation de la tubuline
RU2013141933A (ru) 2011-03-15 2015-03-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные изоксазолидина
UA113508C2 (xx) 2011-03-15 2017-02-10 Ізоксазолідинові похідні
FR3019819B1 (fr) * 2014-04-09 2018-03-23 Centre National De La Recherche Scientifique (Cnrs) Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
CA3097231A1 (fr) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
CN117440954A (zh) * 2021-04-20 2024-01-23 田纳西大学研究基金会 作为微管蛋白聚合抑制剂的代谢稳定的嘧啶基二氢喹喔啉酮

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014716A1 (fr) * 1991-02-20 1992-09-03 Pfizer Inc. Derives de 2,4-diaminoquinazolines stimulant l'activite anti-tumorale
WO2005003100A2 (fr) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. Composes et leur utilisation therapeutique
WO2006014420A1 (fr) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Modulateurs quinazoline d'activite de facteur de croissance hepatocyte/c-met permettant de traiter le cancer
WO2006074147A2 (fr) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Composes et utilisation therapeutique associee

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
AU4342997A (en) * 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
AU4317399A (en) * 1998-05-28 1999-12-13 Parker Hughes Institute Quinazolines for treating brain tumor
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014716A1 (fr) * 1991-02-20 1992-09-03 Pfizer Inc. Derives de 2,4-diaminoquinazolines stimulant l'activite anti-tumorale
WO2005003100A2 (fr) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. Composes et leur utilisation therapeutique
WO2006014420A1 (fr) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Modulateurs quinazoline d'activite de facteur de croissance hepatocyte/c-met permettant de traiter le cancer
WO2006074147A2 (fr) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Composes et utilisation therapeutique associee

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASSEFA, HAREGEWEIN ET AL: "3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors", JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN , 17(8), 475-493 CODEN: JCADEQ; ISSN: 0920-654X, 2003, XP002613543 *
RACHID, ZAKARIA ET AL: "The Combi-Targeting Concept: Chemical Dissection of the Dual Targeting Properties of a Series of "Combi-Triazenes"", JOURNAL OF MEDICINAL CHEMISTRY , 46(20), 4313-4321 CODEN: JMCMAR; ISSN: 0022-2623, 2003, XP002613544 *

Also Published As

Publication number Publication date
KR20070117547A (ko) 2007-12-12
AU2006204052A1 (en) 2006-07-13
CA2592971A1 (fr) 2006-07-13
EP1833511A2 (fr) 2007-09-19
WO2006074187A3 (fr) 2008-01-10
CN101287369A (zh) 2008-10-15
WO2006074187A2 (fr) 2006-07-13
JP2008526776A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
FR21C1062I1 (fr) Traitement combiné de tumeurs exprimant la cd38
EP1991230A4 (fr) Méthodes de traitement du cancer
EP1732650A4 (fr) Composition et methode de traitement du cancer
EP1982660A4 (fr) Endoscope de traitement
EP1667680A4 (fr) Methodes combinees de traitement du cancer
EP1968582A4 (fr) Traitement du lymphome t cutane
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
DE602005012489D1 (de) Verfahren zur Abwasserbehandlung
BRPI0810206A2 (pt) Método de tratar câncer
EP2310006A4 (fr) Traitement du cancer
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1984081A4 (fr) Procédé de traitement oxydatif
EP1677816A4 (fr) Methode de traitement
EP1948182A4 (fr) Methode de traitement de la douleur neuronale et non neuronale
EP1680073A4 (fr) Composes et methode de traitement du cancer
EP2144504A4 (fr) Méthode de traitement du cancer du cerveau
EP2219449A4 (fr) Procédés de traitement de la douleur viscérale
PT2987796T (pt) Boronoftalidas substituídas por halogéneo para o tratamento de infecções
EP1838714A4 (fr) Procedes de traitement de la douleur
EP2124547A4 (fr) Procédé de traitement du cancer
PT2099446E (pt) Método de tratamento de doença inflamatória intestinal
EP1858587A4 (fr) Appareil de traitement esthetique
MA28901B1 (fr) Methode de traitement de cancers
EP1937892A4 (fr) Methode de traitement de materiaux lignocellulosiques
EP2068911A4 (fr) Procédés de traitement du cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070629

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1102261

Country of ref document: HK

R17D Deferred search report published (corrected)

Effective date: 20080110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/517 20060101ALI20080124BHEP

Ipc: A01N 43/54 20060101AFI20080124BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20101222

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20101213BHEP

Ipc: A61K 31/4706 20060101ALI20101213BHEP

Ipc: A61K 31/5377 20060101ALI20101213BHEP

Ipc: A61K 31/517 20060101ALI20101213BHEP

Ipc: A01N 43/54 20060101AFI20080124BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20101230

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1102261

Country of ref document: HK